Management and outcomes of patients with reduced ejection fraction after acute myocardial infarction in cardiac rehabilitation centers

References

• Braunwald E. Heart failure. JACC: Heart Failure 2013;1:1-20
   PubMed Web of Science ®Google Scholar
• Minicucci MF, Azevedo PS, Polegato BF, et al. Heart failure after myocardial infarction: clinical implications and treatment. Clin Cardiol 2011;34:410-14
   PubMed Web of Science ®Google Scholar
• Balady GJ, Ades PA, Bittner VA, et al. Referral, enrollment, and delivery of cardiac rehabilitation/secondary prevention programs at clinical centers and beyond: a presidential advisory from the American Heart Association. Circulation 2011;124:2951-60
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:1810-52
   PubMed Web of Science ®Google Scholar
• Bestehorn K, Wegscheider K, Voller H. Contemporary trends in cardiac rehabilitation in Germany: patient characteristics, drug treatment, and risk-factor management from 2000 to 2005. Eur J Cardiovasc Prev Rehabil 2008;15:312-18
   PubMed Web of Science ®Google Scholar
• Gitt A, Jannowitz C, Karoff M, et al. Treatment patterns and risk factor control in patients with and without metabolic syndrome in cardiac rehabilitation. Vasc Health Risk Manag 2012;8:265-74
   PubMedGoogle Scholar
• Voller H, Gitt A, Jannowitz C, et al. Treatment patterns, risk factor control and functional capacity in patients with cardiovascular and chronic kidney disease in the cardiac rehabilitation setting. Eur J Prev Cardiol 2013;21:1125-33
   PubMed Web of Science ®Google Scholar
• Reibis R, Voller H, Gitt A, et al. Management of patients with ST-segment elevation or non-ST-segment elevation acute coronary syndromes in cardiac rehabilitation centers. Clin Cardiol 2014;37:213-21
   PubMed Web of Science ®Google Scholar
• Deutsche Gesellschaft für Prävention und Rehabilitation von Herz-Kreislauferkrankungen e.V., Koblenz, Germany. Available at: www.dgpr.de [Last accessed 8 October 2014]
   Google Scholar
• Feigenbaum H. Echocardiographic evaluation of cardiac chambers. In: Bussy RK, ed. Echocardiography, 5th edn. Philadelphia: Lea & Febiger, 1994:138-40
   Google Scholar
• Office of Information Products and Data Analytics–CMS. Administrative Claims Data, January to December 2011, from the Chronic Condition Warehouse. 2012. Centers for Medicare & Medicaid Services, Baltimore, MD, USA. Accessed on 21 October 2014
   Google Scholar
• Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61
   PubMed Web of Science ®Google Scholar
• Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-9
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC 2014;63:889-934
   Google Scholar
• Reibis R, Dovifat C, Dissmann R, et al. Implementation of evidence-based therapy in patients with systolic heart failure from 1998–2000. Clin Res Cardiol 2006;95:154-61
   PubMed Web of Science ®Google Scholar
• Cleeman JI, Grundy SM, Becker D, et al. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486-97
   PubMed Web of Science ®Google Scholar
• Klose G, Schwabe U. Lipid lowering drugs [Lipidsenkende Mittel]. In: Arzneiverordnungs-Report 2013. Berlin: Springer, 2013:687f
   Google Scholar
• Feng Q, Wilke RA, Baye TM. Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics 2012;13:579-94
   PubMed Web of Science ®Google Scholar
• Chatzizisis YS, Koskinas KC, Misirli G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010;33:171-87
   PubMed Web of Science ®Google Scholar
• Doggrell SA. The ezetimibe controversy – can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together? Expert Opin Pharmacother 2012;13:1469-80
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. Ezetimibe/simvastatin: a guide to its clinical use in hypercholesterolemia. Am J Cardiovasc Drugs 2012;12:49-56
   PubMed Web of Science ®Google Scholar
• Ijioma N, Robinson JG. Lipid-lowering effects of ezetimibe and simvastatin in combination. Expert Rev Cardiovasc Ther 2011;9:131-45
   PubMedGoogle Scholar
• Montecucco F, Quercioli A, Mach F. Ezetimibe/simvastatin. Expert Opin Drug Saf 2009;8:715-25
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009;18:308-47
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-71
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-219
   PubMed Web of Science ®Google Scholar
• Taylor RS, Davies EJ, Dalal HM, et al. Effects of exercise training for heart failure with preserved ejection fraction: a systematic review and meta-analysis of comparative studies. Int J Cardiol 2012;162:6-13
   PubMed Web of Science ®Google Scholar
• Smart NA, Dieberg G, Giallauria F. Intermittent versus continuous exercise training in chronic heart failure: a meta-analysis. Int J Cardiol 2013;166:352-8
   PubMed Web of Science ®Google Scholar
• Smart NA, Steele M. Systematic review of the effect of aerobic and resistance exercise training on systemic brain natriuretic peptide (BNP) and N-terminal BNP expression in heart failure patients. Int J Cardiol 2010;140:260-5
   PubMed Web of Science ®Google Scholar
• Smart NA, Meyer T, Butterfield JA, et al. Individual patient meta-analysis of exercise training effects on systemic brain natriuretic peptide expression in heart failure. Eur J Prev Cardiol 2012;19:428-35
   PubMed Web of Science ®Google Scholar
• Davies EJ, Moxham T, Rees K, et al. Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis. Eur J Heart Fail 2010;12:706-15
   PubMed Web of Science ®Google Scholar
• Ottenbacher KJ, Karmarkar A, Graham JE, et al. Thirty-day hospital readmission following discharge from postacute rehabilitation in fee-for-service Medicare patients. JAMA 2014;311:604-14
   PubMed Web of Science ®Google Scholar
• Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30 day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA 2013;309:355-63
   PubMed Web of Science ®Google Scholar